9 completed, 3 recruiting, 1 not yet recruiting, 1 unknown. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 9, Recruiting 3, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS) Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes, Vitrectomy, Laser photocoagulation - Proliferative Sickle Cell Retinopathy | Phase 3 | Not yet recruiting | University of Illinois Chicago | 50 | 2026-12-01 | 2026-11-06 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR Vitrectomy, Endolaser, Faricimab - Proliferative Diabetic Retinopathy (PDR) | Phase 3 | Recruiting | Jaeb Center for Health Research | 426 | 2025-08-04 | 2026-11-17 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | Hoffmann-La Roche | 280 | 2024-03-06 | 2026-07-31 |
| Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients Faricimab - Age-Related Macular Degeneration, Diabetic Macular Edema | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2024-03-01 | 2024-08-27 |
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment | Phase 3 | Recruiting | Jaeb Center for Health Research | 600 | 2023-11-21 | 2026-10-23 |
| A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Faricimab, Sham Procedure, Anti-VEGF Therapy - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Hoffmann-La Roche | 1036 | 2021-04-19 | 2025-10-24 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Central Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 729 | 2021-03-02 | 2024-08-06 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Branch Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 553 | 2021-03-02 | 2024-08-06 |
| A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema Faricimab, Sham Procedure - Diabetic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 1479 | 2020-08-05 | 2026-02-09 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 3 | Completed | Hoffmann-La Roche | 658 | 2019-03-11 | 2025-07-11 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Faricimab, Aflibercept, Sham Procedure - Wet Macular Degeneration | Phase 3 | Completed | Hoffmann-La Roche | 671 | 2019-02-19 | 2025-07-23 |
| A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 951 | 2018-10-09 | 2025-07-11 |
| A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Aflibercept, Faricimab, Sham Procedure - Diabetic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 940 | 2018-09-05 | 2025-07-11 |
Retinal Vein Occlusion (3) · Macular Degeneration (2) · Macular Edema (2) · Wet Macular Degeneration (2) · Polypoidal Choroidal Vasculopathy (1) · Vision Disorders (1)
Hoffmann-La Roche (9) · Jaeb Center for Health Research (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University of Illinois Chicago (1) · Yeungnam University College of Medicine (1)
United States (11) · Germany (9) · Italy (9) · Poland (9) · Spain (9) · France (8) · Hungary (8) · Russia (8) · South Korea (8) · Australia (7) · Hong Kong (7) · Singapore (7) · Taiwan (7) · Argentina (6) · Austria (6)
PMID 41534798, PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38758639, PMID 38852921, PMID 40668667, PMID 41712218, PMID 42753135, PMID 42771326, PMID 36912792, PMID 37955955, PMID 39580145, PMID 40107501, PMID 40496217, PMID 41961203, PMID 42005909, PMID 42622958
2017 (2), 2018 (2), UG1EY014231 (2), 2023 (1)